Understanding Capillary Leak Syndrome and Side Effects
At a Glance
Capillary Leak Syndrome (CLS) is a serious side effect of the BPDCN therapy tagraxofusp (Elzonris). Patients must monitor their daily weight and immediately report early warning signs like a sudden weight gain of 2 to 3 pounds in a single day, new swelling, dizziness, or shortness of breath.
While the targeted therapy tagraxofusp (Elzonris) has revolutionized BPDCN treatment, it comes with a unique and serious side effect called Capillary Leak Syndrome (CLS). Understanding CLS is the most important thing you can do to stay safe during your first few cycles of treatment [1][2].
What is Capillary Leak Syndrome?
Think of your smallest blood vessels (capillaries) as pipes. Normally, these pipes are solid enough to keep your blood and essential proteins inside. In Capillary Leak Syndrome, these “pipes” temporarily become “leaky” [3]. Fluid and proteins (specifically albumin) leak out of your bloodstream and into the surrounding spaces in your body, like your skin, lungs, or abdomen [4][5].
This “leak” causes two main problems [3][6]:
- Swelling and Weight Gain: Fluid builds up where it doesn’t belong (edema).
- Low Blood Pressure: Because the fluid is leaving your blood vessels, there is less “volume” to keep your blood pressure at a healthy level.
Early Warning Signs to Watch For
The risk for CLS is highest during your very first cycle of treatment [1][7]. Because of this risk, you will likely be admitted to the hospital for your first 5-day cycle to ensure you have 24/7 monitoring [1].
Whether in the hospital or at home, you are the first line of defense in catching CLS early. You must notify your care team immediately if you notice [6][8]:
- Sudden Weight Gain: A gain of 2 to 3 pounds (about 1 to 1.5 kg) in a single day is a major red flag [9].
- New Swelling: Feeling “tightness” in your ankles, hands, or even around your face [6].
- Dizziness or Lightheadedness: This can be a sign that your blood pressure is dropping [6].
- Shortness of Breath: This may happen if fluid begins to leak into the space around your lungs [6].
How Your Team Monitors and Treats You
Because CLS can be life-threatening if ignored, your medical team will follow a strict monitoring protocol [10][11]:
- Albumin Checks: You will have frequent blood tests to check your albumin levels. If your albumin drops too low, it is a sign that a “leak” may be starting [12][13].
- Daily Weight: You (or your nurses) will weigh you at the same time every morning. This is the most sensitive way to catch fluid buildup early [12][10].
- Vitals: Your blood pressure and heart rate will be checked multiple times a day during treatment [12].
If CLS is suspected, your doctors will likely pause your treatment. During the acute phase of the “leak,” your blood vessels are depleted of fluid. Your team will treat this by giving intravenous steroids or albumin infusions to pull fluid back into the vessels, and they will carefully avoid giving diuretics (“water pills”), which could dangerously lower your blood pressure further [10][13].
Other Potential Side Effects
While CLS is the primary concern, tagraxofusp and other intensive treatments for BPDCN can cause other side effects [12][13]:
- Elevated Liver Enzymes: Your blood tests may show that your liver is temporarily stressed (high ALT or AST), though this often resolves on its own [14][13].
- Low Platelets (Thrombocytopenia): You may be at an increased risk for bruising or bleeding during treatment [12][13].
- Fatigue: Feeling very tired is common as your body works to fight the cancer and handle the therapy [14].
By being “obsessive” about your daily weight and reporting even small changes, you help your team manage these side effects effectively, keeping your treatment on track [11][2].
Common questions in this guide
What are the early warning signs of capillary leak syndrome?
Why do I need to monitor my weight every day during BPDCN treatment?
What is albumin, and why is it checked during tagraxofusp therapy?
How is capillary leak syndrome treated if it develops?
What other side effects might I experience with Elzonris (tagraxofusp)?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my target albumin level, and how often will you be checking it during my treatment cycle?
- 2.At what exact weight gain (e.g., 2 or 3 pounds in 24 hours) should I call the emergency line?
- 3.Will I be staying in the hospital for my first cycle of tagraxofusp to monitor for CLS?
- 4.If I develop CLS, what is the plan for managing it with albumin or steroids?
- 5.How will we manage my other side effects, like changes in liver enzymes or low platelets?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Hammond D, Pemmaraju N
Hematology/oncology clinics of North America 2020; (34(3)):565-574 doi:10.1016/j.hoc.2020.01.005.
PMID: 32336420 - 2
Targeting CD123 in BPDCN: an emerging field.
DiPippo AJ, Wilson NR, Pemmaraju N
Expert review of hematology 2021; (14(11)):993-1004 doi:10.1080/17474086.2021.1988848.
PMID: 34607517 - 3
Recurrent undifferentiated shock: Idiopathic Systemic Capillary Leak Syndrome.
Aroney N, Ure S, White H, Sane S
Clinical case reports 2015; (3(7)):527-30 doi:10.1002/ccr3.280.
PMID: 26273434 - 4
Sjögren's syndrome concurrent with organizing pneumonia with secondary systemic capillary leak syndrome: a case report.
Cao C, Shao Q, Yang H
Scandinavian journal of rheumatology 2021; (50(4)):322-324 doi:10.1080/03009742.2020.1774648.
PMID: 32985306 - 5
Severe cerebral involvement due to idiopathic systemic capillary leak syndrome.
Günes AR, Berlit P, Weber R
Clinical case reports 2016; (4(4)):429-31 doi:10.1002/ccr3.525.
PMID: 27099745 - 6
Systemic capillary leak syndrome.
Druey KM, Arnaud L, Parikh SM
Nature reviews. Disease primers 2024; (10(1)):86 doi:10.1038/s41572-024-00571-5.
PMID: 39543164 - 7
Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
Economides MP, Konopleva M, Pemmaraju N
Therapeutic advances in hematology 2019; (10()):2040620719874733 doi:10.1177/2040620719874733.
PMID: 31579499 - 8
Idiopathic Capillary Leak Syndrome (Clarkson's Disease): First Reported Case in Oman.
Al-Zaabi F, Al-Farhan H, Al-Lawati A, Al-Busaidi M
Oman medical journal 2024; (39(3)):e635 doi:10.5001/omj.2024.17.
PMID: 39015431 - 9
Systemic Capillary Leak Syndrome after Influenza Vaccination in a Peritoneal Dialysis Patient.
Geerse DA, Meynen FM, Gelens MA, et al.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2015; (35(7)):772-3 doi:10.3747/pdi.2014.00194.
PMID: 26703855 - 10
Tagraxofusp Treatment: Implications for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
Morin A, Kechedjian F, Walton P, Tavakoli A
Clinical journal of oncology nursing 2021; (25(2)):E10-E16 doi:10.1188/21.CJON.E10-E16.
PMID: 33739343 - 11
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm.
Lane AA, Papayannidis C, Angelucci E, et al.
Leukemia & lymphoma 2025; (66(14)):2569-2577 doi:10.1080/10428194.2025.2557505.
PMID: 41134616 - 12
Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP, McCue D, Lane AA, Pemmaraju N
Expert review of clinical pharmacology 2019; (12(10)):941-946 doi:10.1080/17512433.2019.1662297.
PMID: 31465247 - 13
Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
Beziat G, Ysebaert L
OncoTargets and therapy 2020; (13()):5199-5205 doi:10.2147/OTT.S228342.
PMID: 32606740 - 14
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Pemmaraju N, Lane AA, Sweet KL, et al.
The New England journal of medicine 2019; (380(17)):1628-1637 doi:10.1056/NEJMoa1815105.
PMID: 31018069
This page provides educational information about Capillary Leak Syndrome and BPDCN treatment side effects. It does not replace medical advice. Always report new symptoms, like sudden weight gain or swelling, to your oncology team immediately.
Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.